Tigecycline is owned by Amneal.
Tigecycline contains Tigecycline.
Tigecycline has a total of 1 drug patent out of which 0 drug patents have expired.
Tigecycline was authorised for market use on 02 August, 2018.
Tigecycline is available in powder;intravenous dosage forms.
The generics of Tigecycline are possible to be released after 07 April, 2033.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US9855335||AMNEAL||Tigecycline composition for injection|| |
(10 years from now)
Market Authorisation Date: 02 August, 2018
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic